Inhibitors targeting sEH have been evaluated including a sEH-selective TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) and a sEH/COX-2-dual inhibitor (PTUPB; 4-(5-phenyl-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide) to treat pain, cancer, hypertension, brain and heart diseases [9]. The gene discussed is EPHX2; the disease is heart disorder.